Margaret E Ackerman
Overview
Explore the profile of Margaret E Ackerman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
190
Citations
5041
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Raja A, Connor R, Ashare A, Weiner J, Wieland-Alter W, Godin A, et al.
Vaccine
. 2025 Mar;
53:126936.
PMID: 40037127
Using serum and bronchoalveolar lavage (BAL) fluid collected from 20 healthy adults (23-37 years, 55 % female) in the United States, we measured immunoglobulin (Ig) A, IgG, and neutralising activity...
2.
Abdullah L, Emiliani F, Vaidya C, Stuart H, Musial S, Kolling F, et al.
Immunity
. 2025 Feb;
58(3):601-615.e9.
PMID: 40020673
Generating balanced populations of CD8 effector and memory T cells is necessary for immediate and durable immunity to infections and cancer. Yet, a definitive understanding of how a diverse CD8...
3.
Carpenter M, Shrestha S, Bharadwaj P, Concetta C, Sharma S, Weiner J, et al.
Hum Immunol
. 2025 Jan;
86(2):111247.
PMID: 39889319
Donor Specific Antibodies (DSAs) are associated with a higher risk of Antibody Mediated Rejection (AMR). However, not all DSAs are pathogenic, and patients that raise DSAs have a wide spectrum...
4.
Kelkar N, Curtis N, Lahey T, Wieland-Alter W, Stout J, Larson E, et al.
bioRxiv
. 2024 Dec;
PMID: 39713388
Development of an effective tuberculosis (TB) vaccine has been challenged by incomplete understanding of specific factors that provide protection against (Mtb) and the lack of a known correlate of protection...
5.
Edupuganti S, Hurt C, Stephenson K, Huang Y, Paez C, Yu C, et al.
Lancet HIV
. 2024 Dec;
12(1):e13-e25.
PMID: 39667379
Background: Multiple broadly neutralising monoclonal antibodies (mAbs) are in development for HIV-1 prevention. The aim of this trial was to test the PGT121.414.LS and VRC07-523LS mAbs for safety and pharmacokinetics...
6.
Goldberg B, Ackerman M
mBio
. 2024 Dec;
16(1):e0190024.
PMID: 39660921
The biologic activities of antibody drugs are dictated by structure-function relationships-emerging from the kind, composition, and degree of interactions with a target antigen and with soluble and cellular antibody receptors...
7.
Gemander N, Kemlin D, Depickere S, Kelkar N, Sharma S, Pannus P, et al.
Vaccine
. 2024 Nov;
44:126544.
PMID: 39608249
Background: Clinical risk factors of deficient immune responses to COVID-19 mRNA vaccination in SARS-CoV-2 naive hemodialysis recipients (HDR) have already been identified. Clinical factors influencing hybrid immunity induced by SARS-CoV-2...
8.
Slein M, Backes I, Kelkar N, Garland C, Khanwalkar U, Sholukh A, et al.
bioRxiv
. 2024 Nov;
PMID: 39605495
Herpes simplex virus (HSV) encodes surface glycoproteins that are host defense evasion molecules, allowing the virus to escape immune clearance. In addition to their role in neuropathogenesis and cell-cell spread,...
9.
Butler S, Ackerman M
Curr Opin Biotechnol
. 2024 Oct;
90:103216.
PMID: 39437676
Novel chimeric antigen receptor (CAR) T cell designs are being developed to overcome challenges with tumor recognition, trafficking, on-target but off-tumor binding, cytotoxicity, persistence, and immune suppression within the tumor...
10.
Xu S, Kelkar N, Ackerman M
iScience
. 2024 Sep;
27(3):109086.
PMID: 39295637
Correlates of protection (CoPs) are key guideposts that both support vaccine development and licensure as well as improve our understanding of the attributes of immune responses that may directly provide...